NCT03311477View on ClinicalTrials.gov

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 6, 2017

Primary Completion Date

March 4, 2019

Study Completion Date

March 4, 2019

Conditions
Advanced Solid Tumors Cancer
Interventions
DRUG

ABBV-399

Intravenous infusion

Trial Locations (2)

411-8777

Shizuoka Cancer Center /ID# 166940, Sunto-gun

104-0045

National Cancer Center Hospital /ID# 166939, Chuo-ku

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY